MoonLake Immunotherapeutics (MLTX) Interest Coverage Ratio (2022 - 2026)

MoonLake Immunotherapeutics' Interest Coverage Ratio history runs 6 years deep, the most recent figure standing at 30.45 for Q1 2026.

• In Q1 2026, Interest Coverage Ratio rose 76.41% year-over-year to 30.45; the TTM figure through Mar 2026 stood at 33.2 (up 77.42% YoY), while the FY2025 annual figure was 33.78, down 488.57% from the prior year.
• Interest Coverage Ratio for Q1 2026 stood at 30.45, down from 29.81 in the prior quarter.
• The five-year high for Interest Coverage Ratio was 2.37 in Q2 2025, with the low at 24265.32 in Q1 2022.
• The 5-year median for Interest Coverage Ratio is 86.9 (2023), against an average of 1594.23.
• The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio sank 5296.03% in 2022, then soared 98.63% in 2023.
• MoonLake Immunotherapeutics' Interest Coverage Ratio stood at 494.61 in 2022, then soared by 82.43% to 86.9 in 2023, then slumped by 122.34% to 193.21 in 2024, then soared by 84.57% to 29.81 in 2025, then slipped by 2.14% to 30.45 in 2026.
• Business Quant data shows MLTX's Interest Coverage Ratio at 30.45 in Q1 2026, 29.81 in Q4 2025, and 22.34 in Q3 2025.